Back to Search
Start Over
Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
- Source :
-
Cancer [Cancer] 2013 Mar 01; Vol. 119 (5), pp. 1042-9. Date of Electronic Publication: 2012 Nov 06. - Publication Year :
- 2013
-
Abstract
- Background: Vascular endothelial growth factor is up-regulated in hepatocellular carcinoma (HCC) and is further up-regulated after transhepatic arterial chemoembolization. The authors of this report conducted a phase 2 trial to evaluate the safety and efficacy of bevacizumab combined with chemoembolization in patients with unresectable HCC.<br />Methods: Patients who had an Eastern Cooperative Oncology Group performance of status 0 to 2, a Child-Pugh score of A or B, and Barcelona Clinic Liver Cancer stage B or C HCC were eligible. Treatment consisted of bevacizumab every 2 weeks and chemoembolization during the third week of a 6-week cycle for up to 3 cycles over 6 months. The primary endpoints were safety and efficacy.<br />Results: Twenty-five patients received chemoembolization and bevacizumab. The most common grade 3 and 4 events after the first treatment cycle were leukocytopenia (12%), fatigue (12%), and hyponatremia (12%). Serious toxicities that had a known association with bevacizumab were observed in 4 patients. Thirty-day mortality was 0%. The median time to tumor progression for the targeted lesions was not reached, and overall survival was 10.8 months. The objective response rate was 60% using enhancement response evaluation criteria, and the disease control rate was 100%.<br />Conclusions: Concurrent treatment with bevacizumab and chemoembolization was safe in carefully selected patients and demonstrated antitumor activity in patients with unresectable HCC. These results support the further development of bevacizumab combined with chemoembolization as a treatment for unresectable HCC.<br /> (Copyright © 2012 American Cancer Society.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized adverse effects
Bevacizumab
Chemoembolization, Therapeutic adverse effects
Combined Modality Therapy
Female
Humans
Male
Middle Aged
Angiogenesis Inhibitors administration & dosage
Antibodies, Monoclonal, Humanized administration & dosage
Carcinoma, Hepatocellular therapy
Chemoembolization, Therapeutic methods
Liver Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1097-0142
- Volume :
- 119
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 23132335
- Full Text :
- https://doi.org/10.1002/cncr.27859